Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | CHRNG | P07510 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRND | Q07001 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 13/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440316 | 1.00 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL440317 | 1.00 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| Propionic Acid SCHEMBL2795314 | 0.89 | DRD2 (0.44) | DRD2SLC6A2SLC6A4SLC6A3CCR1 | |
| SCHEMBL3017275 | 0.87 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL3017272 | 0.87 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL13210768 | 0.87 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL3017278 | 0.87 | DRD2 (0.54) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| Hydrochloric Acid SCHEMBL3013710 | 0.85 | DRD2 (0.53) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 | |
| SCHEMBL10169493 | 0.84 | DRD2 (0.37) | DRD2SLC6A2SLC6A4SLC6A3CCR1 | |
| SCHEMBL2159303 | 0.83 | SLC6A3 (0.41) | DRD2SLC6A2SLC6A4SLC6A3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2471773-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130289063-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8394817-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1448566-B1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| CN-1738824-A | CCR1 antagonists for treatment of intrinsically active demyelinating inflammatory disorders | MILLENNIUM PHARM INC (US) | 2006-02-22 | — | — | CN | disclosed |
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1562954-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| CN-1585772-A | Chemokine receptor antagonists and methods and uses thereof | MILLENNIUM PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS | 2004-06-03 | — | — | US | disclosed |
| WO-2004043965-A1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | DRD2 801/4885SLC6A2 2443/4885SLC6A4 1560/4885 |
| US-20130289063-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR | CCR1, CCRL2, CCR4 | DRD2 801/4885SLC6A2 2443/4885SLC6A4 1560/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885SLC6A2 976/4885SLC6A4 1469/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | DRD2 3542/4885SLC6A2 1174/4885SLC6A4 1806/4885 |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | DRD2 966/4885SLC6A2 2973/4885SLC6A4 1911/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885SLC6A2 976/4885SLC6A4 1469/4885 |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | CCR1, CCR3, CCR4 | DRD2 625/4885SLC6A2 2524/4885SLC6A4 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.